| Old Articles: <Older 2321-2330 Newer> |
|---|
 |
The Motley Fool
August 31, 2005
Stephen D. Simpson |
Sanofi-Aventis: A Mix of News The company gave investors a lot of information for the second quarter, with not all of it positive.   |
The Motley Fool
August 30, 2005
Charly Travers |
A Drug to Make Hearts Happy? Atherogenics has a potential blockbuster in a drug that could reverse the clogging of arteries. Investors, take note. |
BusinessWeek
September 5, 2005
Amy Barrett |
The Pain Is Just Beginning Why the Vioxx debacle will hobble Merck for years to come |
The Motley Fool
August 29, 2005
Nathan Parmelee |
NDCHealth Checks Out Per-Se Technologies and Dutch firm Wolters Kluwer divide and conquer NDCHealth. For shareholders, this means a buyout at approximately 20 times the company's average free cash flow over the last three years. |
BusinessWeek
September 5, 2005
Capell & Arndt |
Drugs Get Smart Future medicines will more effectively target what ails you by tailoring treatment to your specific genetic profile. Personalized medicine will also help prevent another Vioxx. |
BusinessWeek
September 5, 2005
Kerry Capell |
Meeting Leukemia's Diagnostic Challenge Tests that distinguish among the disease's many forms either cost too much or don't exist. Dr. Torsten Haferlach And Switzerland's Roche Diagnostics may have a solution. |
BusinessWeek
September 5, 2005
Michael Arndt |
Fine-Tuning the Attack on Breast Cancer Genentech's Herceptin, the first drug approved for a specific group, helps patients who are genetically susceptible to a virulent form of the disease. |
BusinessWeek
September 5, 2005 |
Putting the FDA Out Front Deputy Commissioner Dr. Janet Woodcock explains how the agency has led the drive for personalized medicine. |
The Motley Fool
August 26, 2005
Stephen D. Simpson |
Merck Broaches the Obvious Merck will naturally end up settling many Vioxx cases, but the details are far from clear at this point. Investors, take note. |
The Motley Fool
August 25, 2005
Stephen D. Simpson |
Another Cavity for Patterson Two straight disappointing quarters have drilled the medical distributor's stock. |
| <Older 2321-2330 Newer> Return to current articles. |
